Mitsubishi Tanabe Pharma Shares Results from Phase 2 Study of ND0612 for Advanced Parkinson’s
Limited Time Offer! For Less Than the Cost of a Starbucks Coffee, Access All DevOpsSchool Videos on YouTube Unlimitedly. Master DevOps, SRE, DevSecOps Skills! Enroll Now Source:-parkinsonsnewstoday.com Continuous delivery of carbidopa/levodopa (CD/LD) with ND0612 under the skin led to quick improvement of clinical status and better quality of life for patients with advanced Parkinson’s disease, according to patient-reported outcomes from a Phase 2 clinical trial. Now, a global Phase 3 study named BouNDless (NCT04006210) is recruiting Parkinson’s patients who have motor fluctuations characterized by the reoccurrence of motor symptoms between levodopa
Read more